We used six solvent additives and a non-volatile DTBT additive to improve the BDTT-S-TR:NIDCS-MO blend morphology for synthesizing high performance all-SMSCs with a promising PCE of 5.33%.
No takes yet. Share an insight, caveat, or question.
Min et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: